CMMB

Chemomab Therapeutics Ltd. Sponsored ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website chemomab.com
Employees(FY) -
ISIN US16385C1045

Performance

-11.35%

+4.46%

+34.43%

+95.01%

+221.57%

YTD

+228.0%

Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Advanced Technical Analysis

Technical Analysis of CMMB 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Oscillators Score of 60 suggests a neutral stance that could support further gains. Overall, the combined Technical Score of 75 reinforces a positive outlook, signaling potential for continued strength in the stock's perf...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CMMB

Stock Rank

Recent News & Updates

2024-11-18 18:00
Oral Presentation at AASLD The Liver Meeting 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis(Globenewswire)
2024-11-13 18:00
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-10-29 19:00
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update(Globenewswire)
2024-10-14 19:00
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting 2024(Globenewswire)
2024-09-30 19:00
Chemomab Therapeutics to Present at October 2024 Investor Conferences(Globenewswire)
2024-08-27 19:00
Chemomab Therapeutics to Present at September 2024 Investor Conferences(Globenewswire)
2024-08-20 19:00
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-08-11 19:00
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update(Globenewswire)
2024-07-29 21:00
Chemomab Therapeutics Announces Closing of $10 Million Private Placement(Globenewswire)
2024-07-25 19:00
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement(Globenewswire)
2024-07-24 19:38
Chemomab Therapeutics Announces $10 Million Private Placement(Globenewswire)
2024-07-24 19:00
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis(Globenewswire)
2024-06-27 00:00
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know(Zacks)
2024-06-17 19:00
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis(Globenewswire)
2024-06-05 19:00
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference(Globenewswire)
2024-05-16 19:00
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences(Globenewswire)
2024-05-09 21:55
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?(Zacks)
2024-05-08 23:57
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024(Investorplace)
2024-05-08 19:00
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-05-07 19:00
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule(Globenewswire)
2024-05-01 19:00
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference(Globenewswire)
2024-04-23 19:00
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update(Globenewswire)
2024-04-17 19:00
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis(Globenewswire)
2024-04-01 19:00
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024(Globenewswire)
2024-03-24 19:06
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis(Globenewswire)
2024-03-06 23:53
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023(Investorplace)
2024-03-06 18:00
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update(Prnewswire)
2024-03-04 18:00
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference(Prnewswire)
2024-02-19 18:00
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases(Prnewswire)
2024-02-13 18:00
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update(Prnewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.